ncAA Incorporation In E. coli

GCEngine platform provides an end-to-end service for site-specific ncAA incorporation in E. coli using orthogonal aaRS/tRNA pairs and codon reassignment (e.g., UAG). The service spans feasibility, assay build-out, quantitative evaluation, and verification. (Research use only; non-GMP.)

Introduction to ncAA Incorporation In E. coli

E. coli remains the most established context for Genetic Code Expansion (GCE). Typical implementations deploy nonsense suppression at UAG with orthogonal aaRS/tRNA (e.g., PylRS/tRNAPyl or engineered TyrRS pairs), often in RF1-attenuated strain backgrounds. Bacterial positive selection (e.g., cat-UAG, +ncAA) and negative selection (e.g., barnase-UAG, −ncAA) are applied to enrich desired variants and penalize ncAA-independent readthrough; fluorescent or luminescent reporters are then used for quantitative ranking, yielding Relative Readthrough Efficiency (RRE) and background metrics. Standardized measurements (e.g., plate reader fluorescence normalized by OD600) enable fair comparison across aaRS/tRNA variants, ncAA dose ranges, and codon contexts. Optional intact-mass or peptide-level LC-MS/MS provides confirmation of site-specific installation and occupancy. Key bottlenecks typically include release-factor competition, background readthrough, and ncAA solubility/uptake, all of which can be mitigated through construct design and process tuning.

Fig.1 Evolved E. coli aaRSs and their preferences for ncAAs. (Furuhata, Y., et al., 2024)

Our Services

Our company provides a turnkey E. coli ncAA incorporation service that moves from feasibility to verification with clear, actionable results: standardized reporters and controls, decision-grade metrics, and documentation your team can reuse. Choose the modules you need or a full package; we handle design, execution, and handover so you can move faster with confidence.

Contact Us

Unlock eukaryotic ncAA capability with measurable efficiency and fidelity gains. Contact us with your use case—display, secretion, or functional screening—and target ncAA panel. We will propose a staged plan with milestones, optional evolution tracks, timelines, and a transparent quote.

Reference

1. Furuhata, Y., et al., (2024). Directed evolution of aminoacyl-tRNA synthetases through in vivo hypermutation. bioRxiv: the preprint server for biology, 2024.09.27.615507.